Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE

Rhea-AI Filing Summary

AstraZeneca PLC reported its updated share capital and voting rights position and confirmed the admission of a small number of new shares. As at 30 April 2026, the company has 1,550,995,630 ordinary shares of US$0.25 each in issue, all carrying voting rights and with no treasury shares held.

A further 14,807 ordinary shares were issued between 1 April 2026 and 30 April 2026 under AstraZeneca’s employee share schemes and admitted to trading on the London Stock Exchange’s Main Market under an existing block admission dated 29 January 2021. These new shares are fully fungible with existing ordinary shares.

Key Figures

Total voting rights: 1,550,995,630 shares Further securities admitted: 14,807 shares Par value per share: US$0.25 per share +2 more

5 metrics

Total voting rights 1,550,995,630 shares Ordinary shares with voting rights as at 30 April 2026

Further securities admitted 14,807 shares Ordinary shares issued under employee share schemes between 1–30 April 2026

Par value per share US$0.25 per share Ordinary shares of AstraZeneca PLC

Block admission date 29 January 2021 Existing block admission under which April 2026 shares were admitted

Admission coverage period 1–30 April 2026 Period during which new scheme shares were issued and admitted

Key Terms

Total Voting Rights, Disclosure and Transparency Rule 5.6.1, Public Offers and Admissions to Trading Regulations 2024, block admission, +1 more

5 terms

Total Voting Rights financial

"Total Voting Rights The following notification is made in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1."

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Disclosure and Transparency Rule 5.6.1 regulatory

"The following notification is made in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1."

Public Offers and Admissions to Trading Regulations 2024 regulatory

"The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R."

block admission regulatory

"Issued between 1 April 2026 to 30 April 2026 (admitted under a block admission dated 29 January 2021)"

employee share schemes financial

"Admission of shares under the Company's employee share schemes from 1 April 2026 up to 30 April 2026"

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights and Admission of Shares

1 May 2026

Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 April 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,995,630 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,995,630.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	14,807
d)	Total number of securities in issue following admission	1,550,995,630
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 April 2026 to 30 April 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 1 April 2026 up to 30 April 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 May 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What total voting rights does AstraZeneca (AZN) report as of 30 April 2026?

AstraZeneca reports 1,550,995,630 total voting rights as of 30 April 2026, corresponding to the same number of ordinary shares of US$0.25 each in issue. The company holds no shares in treasury, so every issued share carries a voting right.

How many new AstraZeneca (AZN) shares were admitted to trading in April 2026?

AstraZeneca admitted 14,807 additional ordinary shares to trading, issued between 1 April 2026 and 30 April 2026. These shares arose from the company’s employee share schemes and were admitted on the London Stock Exchange’s Main Market under an existing block admission dated 29 January 2021.

What is the purpose of AstraZeneca’s April 2026 voting rights disclosure?

The disclosure provides an updated denominator of 1,550,995,630 voting rights that shareholders can use to assess whether they must notify holdings under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, particularly when their percentage interest crosses relevant regulatory reporting thresholds.

Are the newly admitted AstraZeneca (AZN) shares different from existing shares?

The 14,807 new ordinary shares are described as fully fungible with existing Ordinary Shares. This means they have the same rights and characteristics, including voting and economic rights, and trade on the same London Stock Exchange Main Market line as the company’s existing ordinary shares.

Under which programmes were AstraZeneca’s new April 2026 shares issued?

The newly admitted 14,807 shares were issued under AstraZeneca’s employee share schemes. They were admitted to trading on the London Stock Exchange Main Market pursuant to the company’s existing block admission of shares dated 29 January 2021, covering such scheme-related issuances.